Corporate Capture of the Rulemaking Process By

New Post Public Reply Private Reply Replies (0) Message Board
SaltyMutt
Corporate Capture of the Rulemaking Process

By Elizabeth Warren
Jun 14, 2016

(please note: The underlined words are 'clickable' links when accessed via the link at the bottom of this page)

Regulatory capture is a big deal. It is one way in which powerful corporations rig the system to work for themselves—and the rest of America pays the price. The tilt in Congress is pretty much out there for everyone to see, but corporate influence works its magic even better in the shadows—and that’s where rulemaking occurs. This essay focuses on one aspect of this pervasive phenomenon: the capture of agencies as they write the rules.

When it comes to undue industry influence, our rule-making process is broken from start to finish. At every stage, the process is loaded with opportunities for powerful industry groups to tilt the scales in their favor.

The tilt starts early. For example, a 2011 study of U.S. Environmental Protection Agency (EPA) records from 1994 to 2009 found that industry groups held a virtual monopoly over informal communications with EPA that occurred before proposed rules on hazardous air pollutants were publicly available. On average, industry groups engaged in 170 times more informal communications with EPA than public interest players—communications that occurred before any proposed rules were even written.

Similarly, with financial regulation, the big banks and their friends have been lobbying the agencies aggressively. Following the worst financial crisis in three generations—one that resulted in taxpayers spending hundreds of billions to bail out the big banks—Congress passed the Dodd-Frank Wall Street Reform and Consumer Protection Act to ensure that a crisis of that sort never happened again. This law included a provision called the Volcker Rule to stop banks from engaging in certain kinds of risky behavior. But before that rule was even written, groups representing Wall Street interests met with federal regulators 419 times, accounting for over 93 percent of meetings between federal regulators and external parties about the Rule. Less than 7 percent of meetings were with individuals and groups representing the public interest.

As rules wind their way through the process, the lobbying intensifies. When proposed rulemaking notices are published and the public has a formal opportunity to weigh in, their views are quickly buried in an avalanche of detailed, well-funded, well-credentialed comments from industry insiders and their highly-paid allies. Those EPA rules on dangerous air pollutants? Industry groups submitted 81 percent of the comments during the notice-and-comment period. Public interest groups submitted 4 percent.

Some observers argue that this resource mismatch has a smaller impact with agencies than with Congress. Unlike congressional action, agency rules are constrained by well-established judicial review standards that seek to determine whether the agency’s action is supported by the evidentiary record and the authority delegated to it by Congress. Rules must be supported by “substantial evidence”; agency actions must not be “arbitrary and capricious.”

But corporate players are savvy. They have learned that those same judicial review standards can be used to suffocate new rules. They play a sophisticated game—leveraging their own expertise and paying outside experts with purportedly independent credentials to produce long, detailed comments filled with data and analyses, all selectively produced to serve their own interests. This push to bury agencies in detailed, self-serving comments slows the process massively, and their overall dominance of the notice-and-comment process results in rules that are longer, more complicated, and more to the liking of the most powerful players in the game.

Over the last few decades, additional barriers to rulemaking have popped up. Requirements include conducting cost-benefit analyses and evaluating the impact of the rule on small businesses and the environment. Sometimes these processes result in better rules, but often these are just more obstacles that result in even longer, more complex rules, and even more opportunities for well-heeled industry players to slow things down and build in exceptions to benefit themselves.

Consider the Office of Information and Regulatory Affairs, or OIRA, the tiny, obscure, and incredibly powerful agency that reviews significant regulatory proposals developed in other parts of the government before they can take effect. A study of interest group meetings with OIRA showed that between October 1, 2001 to June 1, 2011, OIRA met with five times as many representatives of industry as with people representing public interest groups. And just last year, two professors at the University of Wisconsin-Madison found a strong correlation between interest groups lobbying OIRA and changes in the final rules that favored those interest groups.[1]

These procedures tie agencies in bureaucratic knots and bleed much-needed resources. Often agencies just give up entirely on writing new rules—a situation that tends to play out when Congress or the courts have directed an agency to issue a specific rule by a specific time. A recent study of such deadlines between 1996 and 2014 showed that over 50 percent of final rules were not finished on or before their mandated deadlines. To reiterate, more than half of the time, federal agencies did not meet legally mandated deadlines. For example, Dodd-Frank was passed almost six years ago, but as of today, agencies still have not finalized nearly one quarter of their required rules.

These delays can put lives at risk. Five years ago, Congress passed FDA Food Safety Modernization Act to revamp food safety laws. Regulations were due in 2012. Many were not published until 2015, and then only after a court ordered FDA to publish the regulations. Meanwhile, every year, 3,000 Americans were dying from foodborne illnesses, and 48 million Americans—one in six—was getting sick from contaminated food.

Yet, even if an agency manages to jump through all of the procedural hoops and withstands all the pressure, and actually ultimately issues a final rule, companies will sue. And the rules governing judicial review favor those who would stop the agency from acting in the public interest. Under the law, it is easy for business groups to challenge a rule for being too strong or too restrictive. But it is much harder for public interest groups or ordinary citizens to challenge a rule for being too weak or riddled with loopholes. And it is nearly impossible to challenge successfully an agency for not acting at all.

This certainly takes a toll over time. I talk with agency heads who are like beaten dogs—just trying to keep their heads down. This extreme cautiousness takes an even greater hold over agencies’ general counsels. It is hard to go up against a well-financed machine that will use every tool at its disposal to overturn years of work; it is a lot easier for an agency to give in and write a softer rule—or write no rule at all. Over time, the lobbyists’ work gets done by the agencies’ own lawyers who by this juncture have become so risk averse that they kill off agency action before it even gets off the ground.

To be clear, engaging in informal dialogue, participating in notice-and-comment, and going to court when agencies step out of line are not bad things. But over time, bludgeoning agencies into submission undercuts the public interest. The goal should be to have a system where influence over new rules is measured not by the size of the bankroll, but by the strength of the argument.

Here are a few principles that I believe would balance the scales.

First, increase transparency. The more sunlight that shines on agency processes—and on industry efforts to influence them—the more likely it is that an agency’s final product will reflect the public interest. A good start would be to disclose all meetings between agencies and interested parties, both before and during rulemaking. Another would be to help agencies and courts distinguish between legitimate, high-quality data and research, on the one hand, and bought-and- paid-for studies on the other, by requiring disclosure of financial arrangements and editorial relationships associated with regulatory comments. And anyone who wants to cite their own data should have to publish the dataset online; sure, there need to be safeguards to protect anonymity, for example, but get the data out there where other people can test drive it.

Second, level the playing field between public and private interests. The net effect of a rulemaking process dominated by business advocates is that severely under-resourced public interest advocates are simply out-gunned. States have experimented with systems that build a public advocate into the regulatory process or that compensate public interest advocates who invest resources to produce meaningful feedback on rules. Similarly, judicial review of agencies needs to be reformed to give the public a fighting chance to challenge weak rules, agency inaction, and agency capture.

Third, simplify. Complex rules take longer to finalize, are harder for the public to understand, and inevitably contain more special interest carve-outs that favor big business interests over small businesses and individuals. Complex rules are also more reliant on industry itself to provide additional detail and expertise—and that means more opportunities for capture. Simple works better.

Fourth, limit opportunities for “cultural” capture. Regulators should be beholden to the American people, not to corporate benefactors. Thus, I suggest cracking down on the revolving door, and ending golden parachutes for executives who enter government. In 2013, the Project on Government Oversight released a report showing that major corporations routinely offer their executives financial incentives—to the tune of hundreds of thousands, even millions, of dollars—for accepting government positions. The Financial Services Conflict of Interest Act, a bill introduced by Senator Tammy Baldwin (D-Wis.) and Representative Elijah Cummings (D-Md.), would make these payments illegal under the federal bribery statutes and would target conflicts of interest by removing government employees from decisions that financially benefit their former employers. That is a good start.

Finally, give agencies the money that they need to do their jobs. Writing rules, responding to thousands of comments, and separating valuable data from self-serving nonsense requires capable people with adequate resources. Starving the regulators is the quickest way to ensure that this work is essentially outsourced to the regulated industries themselves.

Regulatory reform is a popular idea, but too many proposals are supported by the industries to be regulated precisely because those proposals would create even more opportunities for them to block regulations that they do not like. Regulatory reform is badly needed, but the reforms must address the central problem—a tilted playing field that benefits the rich and powerful.

Implementing the right kind of reforms will not be easy. The industries that have captured the agencies that are tasked with regulating them will not willingly give up their power and influence. But this is about building a government that works not just for those at the top, but for all of us.

This essay is part of RegBlog’s fifteen-part series, Rooting Out Regulatory Capture.

This essay is based on remarks that Senator Warren delivered at the Regulatory Capture Forum, which the Administrative Conference of the United States convened this spring.

http://www.regblog.org/2016/06/14/warren-corp...g-process/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 295

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 143

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 132

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 143

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 214

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 160

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 185

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 70

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 270

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 69

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading

Top 5 Most Recently Viewed Articles

WTW Welcomes Dale Porfilio as Director for Business Development

Updated Category News Views 138

WTW Appoints New Leader for Business Development In a significant move to enhance its operations, WTW (NASDAQ: WTW) has announced the appointment of Dale Porfilio as Senior Director and Head of Personal and Commercial Lines Business Development within its Insurance Consulting & Technology (ICT) segment. A Seasoned Professional Joins WTW Porfilio brings a wealth of...

Continue Reading
Jorgen Vig Knudstorp's Bold Stock Purchase at Starbucks

Updated Category News Views 74

Jorgen Vig Knudstorp Invests in Starbucks, Showing Strong Confidence Recently, Jorgen Vig Knudstorp, a director at Starbucks Corp (NASDAQ:SBUX), made a significant move by buying shares of the company. This act signals a firm vote of confidence in the future of the beloved coffee chain. When insiders make such investments, it often grabs the attention of other investors...

Continue Reading
Understanding Inventiva's Latest Half-Year Report and Future Plans

Updated Category News Views 65

Inventiva Files its 2024 Half-Year Report Inventiva, a prominent clinical-stage biopharmaceutical company, is making significant strides in the healthcare sector. Focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis, commonly known as MASH/NASH, the company recently announced its filing of the 2024 Half-Year Report for the period...

Continue Reading
Analyzing Organon's Upcoming Earnings Announcement and Insights

Updated Category News Views 177

Anticipation Surrounding Organon's Earnings Report Organon (OGN) is on the verge of revealing its quarterly earnings report, a moment eagerly awaited by investors. As preparations finalize for this significant announcement, understanding the forecasted outcomes can guide investor decisions moving forward. Expected Earnings Figures Forecast estimates suggest that Organon...

Continue Reading
Miami Real Estate Trends: A Surge in Older Condo Sales

Updated Category News Views 180

Understanding the Miami-Dade Real Estate Market Miami-Dade County's real estate landscape is shifting, with older condominiums experiencing quicker sales than their newer counterparts. This trend indicates a solid demand for older condos, highlighting their appeal in a market where affordable housing options continue to thrive. Statistical data reveal that older...

Continue Reading